Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12464755 | 0.87 | — | — | |
| SCHEMBL17340159 | 0.87 | — | — | |
| SCHEMBL12397956 | 0.80 | — | — | |
| SCHEMBL12397931 | 0.75 | ESR2 (0.34) | RECQLSMN1; SMN2 | |
| SCHEMBL21057413 | 0.73 | — | — | |
| SCHEMBL21057412 | 0.73 | — | — | |
| SCHEMBL12397951 | 0.71 | — | — | |
| SCHEMBL21138385 | 0.71 | NAMPT (0.36) | SMN1; SMN2 | |
| SCHEMBL3185280 | 0.69 | — | — | |
| SCHEMBL13531907 | 0.67 | ESR2 (0.38) | RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212136-B2 | Methods for producing paricalcitol | AZAD PHARMACEUTICALS INGREDIENTS AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20110184199-A1 | Methods For Producing Paricalcitol | AZAD PHARMA AG (CH) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184199-A1 | Methods For Producing Paricalcitol | CYP2R1, PTH1R, CYP24A1 | RECQL 2865/4885SMN1; SMN2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.